News-Events

CBI e-Newsletter/CBI Report

Collaborative Innovation > Transformational Impact

April 2007 - Vol 2, Issue 1

In This Issue

  • Kauffman Foundation Awards $60,000 Gift
  • New Founding Members Join CBI
  • Frank Douglas to Receive Black History Makers Award
  • Mark McClellan Joins CBI S&P Council
  • CBI's TRPs in Spotlight
  • Members Only Conference

Join our Mailing List

View Newsletter Archive

Dr. Frank Douglass

Welcome to the first CBI Newsletter of 2007. As you will see, there is a great deal of activity at the Center--almost too much to put in one newsletter! It's been a busy time, and we look forward to even more exciting and important news in the coming months. Please remember to check our web site (http://web.mit.edu/cbi) for updates and new developments. I know you'll find much news of interest.

Regards,


Frank L. Douglas

 

 


CBI NEWS

New Founding Members Join CBI

We are pleased to welcome several new Founding Members who have joined with CBI to help further our mission. Since our last newsletter the following companies have joined:

  • Amgen
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Baxter International
  • Vertex Pharmaceuticals Inc.

Read more about these new members on our website's press release page

Kauffman Foundation Awards $60,000 Gift to CBI

In January, CBI received a $60,000 gift from the Ewing Marion Kauffman Foundation to further the Center's leading edge work to transform global healthcare innovation and delivery. "We believe that CBI's approach, which emphasizes research that has real world impacts, has tremendous potential for the delivery of healthcare," said Lesa Mitchell, the Kauffman Foundation's Vice President for Advancing Innovation.

You can download the full article as a PDF here

New Paper by Trusheim, Berndt and Douglas in Nature Reviews Drug Discovery

"Stratified Medicine: Strategic and Economic Implications of Combining Drugs and Clinical Biomarkers," by CBI members Mark R. Trusheim, Ernst R. Berndt and Frank L. Douglas, is available in the current issue of Nature Reviews Drug Discovery.


You can read the article here

Dr. Frank Douglas Receives Black History Makers Award

CBI Executive Director Frank L. Douglas, M.D., Ph.D. was named a 2007 "Black History Maker" by Associated Black Charities. Dr. Douglas is one of five recipients honored at the New York Marriott Marquis on April 11, 2007. Past recipients have included U.N. Secretary General Kofi Annan, Colin Powell, Vernon Jordan, Justice Thurgood Marshall and other notables.

Read more . . .

Dr. Mark McClellan Joins CBI Strategy & Policy Council

Dr. Mark McClellan Mark McCllellan, M.D., Ph.D., former Commissioner of the FDA and Administrator for the Centers for Medicare and Medicaid Services, has joined the CBI Strategy & Policy Council. Prior to joining the FDA, Dr. McClellan was Associate Professor of Economics at Stanford University, Associate Professor of Medicine at Stanford Medical School, a practicing internist, and Director of the Program on Health Outcomes Research at Stanford University.The Strategy & Policy Council serves as a major advisory committee, helping to guide CBI research activities and the development of initiatives and projects.

 

CBI UPDATE: The Center's TRPs

CBI's Research Agenda focuses on four broad areas which have critical importance to the biomedical value chain: Safety Assessment; Redesigning R&D; Economic, Financial & Risk Management; and Manufacturing & Distribution. Within these areas, focused Transformational Research Projects (TRPs) are conducted by cross-disciplinary Working Groups, led by Principal Investigators from MIT or Harvard and co-led by industry experts. TRPs seek to generate new tools, insights and methods that are demonstrably effective in applied biomedical settings.

Here's an update on CBI's Research Areas and their Leaders, and the active TRPs in those areas and their co-leaders:

SAFETY ASSESSMENT

  • Reseach Area Leaders:
  • Steven R. Tannenbaum, PhD-MIT
  • Isaac Kohane, MD, PhD-MIT & Childrens' Hospital
  • Post Marketing Surveillance:
  • Kenneth Mandl, MD, MPH-Harvard Medical School
  • Piet Vervaet, MD-AstraZeneca
  • Drug Development and the Liver Project:
  • Steven R. Tannenbaum, PhD-MIT
  • Frank L. Douglas, PhD, MD-MIT

REDESIGNING R&D

  • Research Area Leaders:
  • Thomas J. Allen, PhD-MIT
  • Frank L. Douglas, PhD, MD-MIT

R&D Productivity: Enhancing the Probability of Success - This TRP consists of three sub-projects:
  • Innovative R&D Metrics:
  • Kevin Nguyen-Vertex Pharmaceuticals
  • Martin Bechem, PhD-Bayer
  • Asher Schacter, MD, MMSc, MS-Harvard Medical School 

  • Go/No Go Decision Analysis:
  • Kevin Nguyen-Vertex Vertex Pharmaceuticals
  • Martin Bechem, PhD-Bayer
  • Asher Schacter, MD, MMSc, MS-Harvard Medical School 

  • Enhancing Productivity in Collaborative Innovation: Frank Douglas-MIT
  • Lesa Mitchell-Kauffman Foundation
  • Ernst Berndt, PhD-MIT 
  • Streamlining Clinical Trial Operations:
  • Frank L. Douglas-MIT
  • John Orloff, MD-Novartis

  • Central Nervous System (CNS) Biomarkers: Placebo vs. Non-responders:
  • Alexa Kimball, MD, MPH-Harvard Medical School 
  • Stephen Furlong-PhD-AstraZeneca 
  • Frank L. Douglas-MIT

ECONOMIC, FINANCIAL & RISK MANAGEMENT

  • Reseach Area Leaders:
  • Ernst R. Berndt, PhD-MIT
  • Frank L. Douglas

  • Economics of Stratified Medicine:
  • Ernst Berndt-MIT
  • Mark Trusheim-MIT
  • Frank Douglas-MIT

  • Tracking the Evolution of Clinical Trial Design:
  • Ernst Berndt-MIT
  • Frank Douglas-MIT

MANUFACTURING & DISTRIBUTION SYSTEMS

  • Reseach Area Leaders:
  • Anthony J. Sinskey, ScD-MIT
  • Charles L. Cooney, PhD-MIT

  • Follow On Biologics:
  • Frank L. Douglas-MIT
  • Ram Sasisekharan, PhD-MIT
  • Ajaz Hussain, PhD-Sandoz
  • Streamlining Manufacturing
  • Anthony Sinskey, ScD-MIT
  • Rajeev Ram, PHD-MIT

  • Vaccines Project:
  • Anthony Sinskey, Sc.D.-MIT
  • Rajeev Ram, PhD-MIT

For a complete description of these TRPs, their goals and activities, see our web site section on TRPs.

AN UPCOMING  SPECIAL EVENT FOR CBI MEMBERS ONLY

On May 10, CBI will co-sponsor a special invitational conference, "FROM INNOVATION TO IMPACT: Healthcare IT Strategies to Bridge the Gap", with PRIME ("Pharmaceutical R&D Information Management Executive" Forum); This special conference, taking place in Cambridge, will feature several high-level presentations from CBI researchers and industry members. If you are involved in information management, you won't want to miss this conference--but your firm must be a CBI, PRIME or IMPACC member to attend. For more information, contact CBI at (617) 253-0687.

UPCOMING CBI EVENTS

  • Strategy & Policy Council Meeting - May 21, 2007, Cambridge
  • The Placebo Study Workshop-by invitation - June 1, 2007
  • R&D Metrics Workshop-by invitation - TBA
  • 3rd Annual Stakeholders' Summit - October 10-11, 2007

Thanks again for your interest and support for CBI.
Best regards,

Frank Douglas
CBI

Center for Biomedical Innovation

email: mottley@mit.edu
phone: (617) 253-0257
web: http://web.mit.edu/cbi